{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:39:43Z","timestamp":1790977183514,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004599","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2019119"],"award-info":[{"award-number":["2019119"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["26011"],"award-info":[{"award-number":["26011"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtho.2026.103992","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:52:26Z","timestamp":1782229946000},"page":"103992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-6116","authenticated-orcid":false,"given":"Henrik","family":"Horndalsveen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilde Drageset","family":"Haakensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesfaye","family":"Madebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Henning","family":"Gr\u00f8nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarje Ons\u00f8ien","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Moksnes","family":"Bjaan\u00e6s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britina Kjuul","family":"Danielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"B\u00f8rve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig","family":"Kokkvoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonje Sofie Dalen","family":"Boda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa Kristina","family":"\u00d6jlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5slaug","family":"Helland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103992_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2026.103992_bib2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103992_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2026.103992_bib6","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","article-title":"Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: a systematic review and meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2026.103992_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1253629","article-title":"ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy","volume":"13","author":"Lebow","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib8","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.diii.2016.06.019","article-title":"Imaging after radiation therapy of thoracic tumors","volume":"97","author":"Ghaye","year":"2016","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.jtho.2026.103992_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.seminoncol.2018.01.007","article-title":"Surveillance imaging following definitive radiotherapy for non-small cell lung cancer: what is the clinical impact?","volume":"44","author":"Dyer","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.542","article-title":"Durvalumab induced sarcoid-like pulmonary lymphadenopathy","volume":"8","author":"Sanderson","year":"2020","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jtho.2026.103992_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib12","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.3390\/cancers15102702","article-title":"Liquid biopsy in early-stage lung cancer: current and future clinical applications","volume":"15","author":"Vandekerckhove","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2026.103992_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103899","article-title":"Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: making the invisible visible","volume":"182","author":"Gristina","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtho.2026.103992_bib14","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.103992_bib15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.21.01929","article-title":"Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent","volume":"40","author":"Pellini","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.055","article-title":"LBA59 associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial","volume":"34","author":"Reck","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib17","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103992_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21037\/tlcr-22-106","article-title":"Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients","volume":"11","author":"Yue","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2026.103992_bib19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41392-023-01700-4","article-title":"Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2026.103992_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8009","article-title":"Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial","volume":"43","author":"Reck","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO-24-02239","article-title":"Neoadjuvant nivolumab plus ipilimumab versus chemotherapy in resectable lung cancer","volume":"43","author":"Awad","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12916-022-02681-x","article-title":"Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer","volume":"20","author":"Shen","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.jtho.2026.103992_bib23","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.103992_bib24","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/1878-0261.13116","article-title":"Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer","volume":"16","author":"Waldeck","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/1878-0261.13387","article-title":"Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study","volume":"17","author":"Fu","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib27","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","article-title":"Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients","volume":"41","author":"Pan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2026.103992_bib28","first-page":"177","article-title":"Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy","volume":"4","author":"Wang","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.jtho.2026.103992_bib29","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jtho.2024.06.024","article-title":"Analysis of circulating tumor DNA predicts outcomes of short-course consolidation immunotherapy in unresectable stage III NSCLC","volume":"19","author":"Jun","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib30","article-title":"ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach","volume":"39","author":"Nielsen","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jtho.2026.103992_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2292","article-title":"LBA51 circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial","volume":"35","author":"Filippi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108528","article-title":"ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach","volume":"203","author":"Rosenlund","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103992_bib33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12916-023-02849-z","article-title":"Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis","volume":"21","author":"Zhong","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.jtho.2026.103992_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1681420","article-title":"Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab","volume":"15","author":"Horndalsveen","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2026.103992_bib35","article-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","author":"Li","year":"2013","journal-title":"arXiv preprint arXiv:13033997"},{"key":"10.1016\/j.jtho.2026.103992_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw227","article-title":"VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research","volume":"44","author":"Lai","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtho.2026.103992_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156529","article-title":"Circulating cell-free methylated DNA reveals tissue-specific, cellular damage from radiation treatment","volume":"8","author":"McNamara","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtho.2026.103992_bib39","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non\u2013small cell lung cancer","volume":"79","author":"Anagnostou","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.103992_bib40","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2026.103992_bib41","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.103992_bib42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.103992_bib43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.103992_bib44","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.103992_bib45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/jmp2030022","article-title":"Liquid biopsy for biomarker testing in non-small cell lung cancer: a European perspective","volume":"2","author":"Malapelle","year":"2021","journal-title":"J Mol Pathol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426004454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426004454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:41:00Z","timestamp":1790934060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426004454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1556086426004454"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103992","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103992"}}